Dec. 1 at 5:06 PM
$MARK The global AI in cancer diagnostics market is projected to grow from about
$1.07B in 2024 to
$2.61B by 2034 at a 9.35% CAGR, Mainz Biomed’s mRNA and stool data are exactly the kind of structured datasets AI loves, so I see Mainz Biomed as a natural beneficiary of that
$2.6B AI tailwind and price in a
$14 target to reflect that 🚀